In this issue:
Updates to NCCN Clinical Practice Guidelines
Systemic therapy for melanoma: ASCO Guideline Update
Redesigning SLNB guidelines for melanoma
Implications of the NICE 2022 guidelines on the management of melanoma
RELATIVITY-047: durable PFS benefit to nivolumab + relatlimab for unresectable disease
mRNA vaccine + pembrolizumab may be a novel adjuvant therapy for high-risk melanoma
Positive results from world-first phase 1 MIMic trial of FMT in melanoma
PBAC recommendations
Australian clinical practice guidelines for the diagnosis and management of melanoma
Melanoma Institute Australia partners with Toyota Material Handling
FDA approves melphalan as a liver-directed treatment for uveal melanoma
Racial and ethnic differences in males with melanoma
COVID-19 resources
Conferences, workshops and CPD
Please login below to download this issue (PDF)